Yot Teerawattananon,1 Sripen Tantivess,1 Pitsaphun Werayingyong,1 Pritaporn Kingkaew,1 Nilar Tin,2 San San Aye,3 Phone Myint3 Abstract Introduction: In 2010, with financial support from the Global Alliance for Vaccine and Immunization’s Health System Strengthening programme, the Government of

Pitsaphun Werayingyong, BPharm, MSc1, Nittaya Phanuphak, MD2, Kulkunya Chokephaibulkit, MD3, Sripen Tantivess, BPharm, PhD1, Nareeluk Kullert, BSc4, Kakanang Tosanguan, BPharm1, Rukmanee Butchon, MSc1, Nipunporn Voramongkol, MD4, Sarawut Boonsuk, MD5, Songyot Pilasant, BSc1, Wantanee Kulpeng, BSc1,

Boonying Siribumrungwong , Pinit Noorit , Chumpon Wilasrusmee, Yot Teerawattananon, Ammarin Thakkinstian Summary Background/Objective To determine the quality of life (QoL) in Thais after intervention for great saphenous vein (GSV) reflux. Methods Patients with Clinical Etiologic Anatomic

Boonying Siribumrungwong1, Pinit Noorit2, Chumpon Wilasrusmee3, Pattara Leelahavarong4, Ammarin Thakkinstian5 and Yot Teerawattananon4 Abstract Objectives: To conduct economic evaluations of radiofrequency ablation, ultrasound-guided foam sclerotherapy and surgery for great saphenous vein ab

Improving quality of primary care through financial incentives: the case of Thailand. Paramjit Gill1, Rachel Foskett-Tharby1, Francoise Cluzeau2, Sripen Tantivess3 and Yot Teerawattananon3 1National Collaborating Centre for Indicator Development, University of Birmingham, UK 2NICE International

Pritaporn Kingkaew1,*, PitsaphunWerayingyong1, San San Aye2, Nilar Tin3, Alaka Singh4, Phone Myint2 and Yot Teerawattananon1 1Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand, 2Department of Health Planning and 3Department of He

Songyot Pilasant1, Wantanee Kulpeng1, Pitsaphun Werayingyong1*, Nattha Tritasavit1, Inthira Yamabhai1, Yot Teerawattananon1, Sangay Wangmo2 and Sripen Tantivess1 Abstract Background: The Maternal and Child Health Voucher Scheme (MCHVS) was introduced in Myanmar to address the high rate of mat

Generic reference cases for economic evaluation (EE) of “cure-based” health technologies may not fit into the new healthcare paradigm of precision medicine (PM). Current EE approaches were challenged by the complex evolving decision space of PM, lack of clinical evidence due to small patient cluster

Introduction Genetic disorders in children contribute to acute hospitalizations and mortality. Early diagnosis is critical for better outcomes but difficult to achieve due to atypical presentations for thousands of potential genetic diseases. Next-generation sequencing (NGS) is a precision

About the study Objective: This study aimed to quantify heterogeneity in the value for money of precision medicine (PM) by application types across contexts and conditions and to quantify sources of heterogeneity to areas of particular promises or concerns as the field of PM moves forward. Methods